<p>Cingulate (NASDAQ:CING - 獲取免費報告) 預計將在 2026 年 5 月 14 日星期四市場開盤前發佈其 2026 年第一季度的財報。分析師預計該公司本季度每股收益為（$0.53）。各方可以在公司即將發佈的 2026 年第一季度財報頁面找到電話會議的詳細信息，最新的電話會議安排在 2026 年 5 月 15 日星期五上午 9:30（東部時間）。</p>
<p>Cingulate (NASDAQ:CING - 獲取免費報告) 最近在 3 月 18 日星期三公佈了季度財報。該公司報告每股收益（EPS）為（$0.84），低於分析師一致預期的（$0.56），差距為（$0.28）。平均而言，分析師預計 Cingulate 在當前財年將發佈每股收益為 $-2，下一財年為 $-1。</p>
<h2>Cingulate 股票上漲 7.0%</h2>
<p>NASDAQ:CING 的股票在星期四以 $5.33 開盤。Cingulate 的一年低點為 $3.20，一年高點為 $11.89。該公司的市值為 6530 萬美元，市盈率為 -1.23，貝塔值為 -0.81。公司的債務與股本比率為 0.46，流動比率為 1.16，速動比率為 1.16。該股票的 50 日移動平均線為 $6.46，200 日移動平均線為 $5.24。</p>
<h2>分析師升級與降級</h2>
<p>CING 一直是多份研究分析師報告的主題。Roth Mkm 在 3 月 23 日星期一的報告中將 Cingulate 的目標價從 $16.00 下調至 $14.00，並對該股票給予 “買入” 評級。Weiss Ratings 在 4 月 20 日星期一的報告中重申了對 Cingulate 股票的 “賣出（e+）” 評級。最後，Ascendiant Capital Markets 在 4 月 8 日星期三的報告中將 Cingulate 的目標價從 $58.00 下調至 $55.00，並對該股票給予 “買入” 評級。兩位研究分析師對該股票給予了買入評級，一位則給予了賣出評級。根據 MarketBeat.com 的數據，Cingulate 目前的共識評級為 “持有”，平均目標價為 $34.50。</p>
<p><strong>獲取我們關於 CING 的最新研究報告</strong></p>
<h2>內部人士買賣</h2>
<p>在其他新聞中，董事彼得·J·沃斯於 2 月 6 日星期五購買了 19,455 股 Cingulate 股票。每股購買價格為 $5.04，總交易額為 $98,053.20。收購後，該董事持有 117,449 股公司股票，估值約為 $591,942.96。這筆交易使他們的持股增加了 19.85%。該收購已在與 SEC 的法律文件中披露，可以通過此鏈接訪問。此外，首席執行官香農·J·沙弗於 2 月 6 日星期五購買了 6,809 股 Cingulate 股票。每股購買價格為 $5.04，總交易額為 $34,317.36。收購後，首席執行官直接持有公司 10,175 股股票，估值約為 $51,282。這筆交易代表了他們持股的 202.29% 增加。該購買的披露信息可在 SEC 文件中找到。內部人士在上個季度共購買了價值 $166,693 的 33,074 股公司股票。公司內部人士持有公司股票的 4.33%。</p>
<h2>機構資金流入與流出</h2>
<p>一些對沖基金和其他機構投資者最近對公司的持倉進行了調整。Kestra Advisory Services LLC 在第四季度將其在 Cingulate 股票中的持倉增加了 29.8%。Kestra Advisory Services LLC 現在擁有 122,000 股公司股票，價值 $529,000，此前在此期間又收購了 27,979 股。Geode Capital Management LLC 在第四季度將其在 Cingulate 股票中的持倉增加了 43.9%。Geode Capital Management LLC 現在擁有 61,035 股公司股票，價值 $265,000，此前在此期間又收購了 18,629 股。DRW Securities LLC 在第四季度購買了 Cingulate 的新頭寸，價值約為 $255,000。XTX Topco Ltd 在第四季度購買了 Cingulate 的新頭寸，價值約為 $90,000。最後，Quadrature Capital Ltd 在第四季度購買了 Cingulate 的新股份，價值約為 $66,000。對沖基金和其他機構投資者持有公司股票的 41.31%。</p>
<h2>Cingulate 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Cingulate Inc 是一家生物製藥公司，專注於開發用於治療美國注意力缺陷/多動障礙和焦慮的藥物。該公司的興奮劑藥物包括 CTx-1301（右甲基苯丙胺），目前處於三期臨牀試驗階段，以及 CTx-1302（右旋安非他命），目前正在進行新藥申請開發，旨在治療兒童、青少年和成人的注意力缺陷/多動障礙。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Cingulate</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0lORw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0lORw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 $1,000 在 Cingulate 嗎？</h2>
<p>在你考慮 Cingulate 之前，你會想聽聽這個。</p>
<p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每天推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買... 而 Cingulate 並不在名單上。</p>
<p>雖然 Cingulate 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

CING

紐交所高增長板生物技術指數 ETF - First Trust

標普生物技術 3 倍做多 - Direxion

<p>Cingulate (NASDAQ:CING) 將於 5 月 14 日發佈 2026 年第一季度財報，分析師預計每股虧損 0.53 美元。該公司此前報告了 2025 年第一季度每股虧損 0.84 美元，未能達到預期。Cingulate 的股票最近上漲了 7%，交易價格為 5.33 美元，市值為 6530 萬美元。內部人士的買入活動增加，董事彼得·J·沃斯（Peter J. Werth）和首席執行官香農·J·沙弗（Shane J. Schaffer）進行了大量購買。機構投資者持有該公司 41.31% 的股份，公司專注於注意力缺陷多動障礙（ADHD）和焦慮症的治療</p>

<p>Cingulate (NASDAQ:CING - Get Free Report) is expected to issue its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect the company to announce earnings of ($0.53) per share for the quarter. Parties can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Friday, May 15, 2026 at 9:30 AM ET.</p>
<div class="lb-trans"><p>Cingulate (NASDAQ:CING - 獲取免費報告) 預計將在 2026 年 5 月 14 日星期四市場開盤前發佈其 2026 年第一季度的財報。分析師預計該公司本季度每股收益為（$0.53）。各方可以在公司即將發佈的 2026 年第一季度財報頁面找到電話會議的詳細信息，最新的電話會議安排在 2026 年 5 月 15 日星期五上午 9:30（東部時間）。</p>
</div><p>Cingulate (NASDAQ:CING - Get Free Report) last announced its quarterly earnings results on Wednesday, March 18th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.28). On average, analysts expect Cingulate to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>Cingulate (NASDAQ:CING - 獲取免費報告) 最近在 3 月 18 日星期三公佈了季度財報。該公司報告每股收益（EPS）為（$0.84），低於分析師一致預期的（$0.56），差距為（$0.28）。平均而言，分析師預計 Cingulate 在當前財年將發佈每股收益為 $-2，下一財年為 $-1。</p>
</div><h2>Cingulate Stock Up 7.0%</h2>
<div class="lb-trans"><h2>Cingulate 股票上漲 7.0%</h2>
</div><p>Shares of NASDAQ:CING opened at $5.33 on Thursday. Cingulate has a 1 year low of $3.20 and a 1 year high of $11.89. The company has a market cap of $65.30 million, a PE ratio of -1.23 and a beta of -0.81. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.16 and a quick ratio of 1.16. The stock's 50-day moving average is $6.46 and its 200 day moving average is $5.24.</p>
<div class="lb-trans"><p>NASDAQ:CING 的股票在星期四以 $5.33 開盤。Cingulate 的一年低點為 $3.20，一年高點為 $11.89。該公司的市值為 6530 萬美元，市盈率為 -1.23，貝塔值為 -0.81。公司的債務與股本比率為 0.46，流動比率為 1.16，速動比率為 1.16。該股票的 50 日移動平均線為 $6.46，200 日移動平均線為 $5.24。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師升級與降級</h2>
</div><p>CING has been the topic of a number of research analyst reports. Roth Mkm reduced their price target on Cingulate from $16.00 to $14.00 and set a &#34;buy&#34; rating on the stock in a report on Monday, March 23rd. Weiss Ratings restated a &#34;sell (e+)&#34; rating on shares of Cingulate in a report on Monday, April 20th. Finally, Ascendiant Capital Markets reduced their price target on Cingulate from $58.00 to $55.00 and set a &#34;buy&#34; rating on the stock in a report on Wednesday, April 8th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Cingulate currently has a consensus rating of &#34;Hold&#34; and an average price target of $34.50.</p>
<div class="lb-trans"><p>CING 一直是多份研究分析師報告的主題。Roth Mkm 在 3 月 23 日星期一的報告中將 Cingulate 的目標價從 $16.00 下調至 $14.00，並對該股票給予 “買入” 評級。Weiss Ratings 在 4 月 20 日星期一的報告中重申了對 Cingulate 股票的 “賣出（e+）” 評級。最後，Ascendiant Capital Markets 在 4 月 8 日星期三的報告中將 Cingulate 的目標價從 $58.00 下調至 $55.00，並對該股票給予 “買入” 評級。兩位研究分析師對該股票給予了買入評級，一位則給予了賣出評級。根據 MarketBeat.com 的數據，Cingulate 目前的共識評級為 “持有”，平均目標價為 $34.50。</p>
</div><p><strong>Get Our Latest Research Report on CING</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 CING 的最新研究報告</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部人士買賣</h2>
</div><p>In other news, Director Peter J. Werth bought 19,455 shares of Cingulate stock in a transaction on Friday, February 6th. The shares were purchased at an average price of $5.04 per share, for a total transaction of $98,053.20. Following the acquisition, the director owned 117,449 shares of the company's stock, valued at approximately $591,942.96. The trade was a 19.85% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Shane J. Schaffer bought 6,809 shares of Cingulate stock in a transaction on Friday, February 6th. The shares were purchased at an average price of $5.04 per share, for a total transaction of $34,317.36. Following the acquisition, the chief executive officer directly owned 10,175 shares in the company, valued at approximately $51,282. This trade represents a 202.29% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 33,074 shares of company stock worth $166,693 in the last quarter. Company insiders own 4.33% of the company's stock.</p>
<div class="lb-trans"><p>在其他新聞中，董事彼得·J·沃斯於 2 月 6 日星期五購買了 19,455 股 Cingulate 股票。每股購買價格為 $5.04，總交易額為 $98,053.20。收購後，該董事持有 117,449 股公司股票，估值約為 $591,942.96。這筆交易使他們的持股增加了 19.85%。該收購已在與 SEC 的法律文件中披露，可以通過此鏈接訪問。此外，首席執行官香農·J·沙弗於 2 月 6 日星期五購買了 6,809 股 Cingulate 股票。每股購買價格為 $5.04，總交易額為 $34,317.36。收購後，首席執行官直接持有公司 10,175 股股票，估值約為 $51,282。這筆交易代表了他們持股的 202.29% 增加。該購買的披露信息可在 SEC 文件中找到。內部人士在上個季度共購買了價值 $166,693 的 33,074 股公司股票。公司內部人士持有公司股票的 4.33%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入與流出</h2>
</div><p>A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Kestra Advisory Services LLC grew its holdings in shares of Cingulate by 29.8% during the 4th quarter. Kestra Advisory Services LLC now owns 122,000 shares of the company's stock worth $529,000 after acquiring an additional 27,979 shares during the period. Geode Capital Management LLC grew its holdings in shares of Cingulate by 43.9% during the 4th quarter. Geode Capital Management LLC now owns 61,035 shares of the company's stock worth $265,000 after acquiring an additional 18,629 shares during the period. DRW Securities LLC purchased a new position in shares of Cingulate during the 4th quarter worth approximately $255,000. XTX Topco Ltd purchased a new position in shares of Cingulate during the 4th quarter worth approximately $90,000. Finally, Quadrature Capital Ltd purchased a new stake in shares of Cingulate in the 4th quarter worth approximately $66,000. Hedge funds and other institutional investors own 41.31% of the company's stock.</p>
<div class="lb-trans"><p>一些對沖基金和其他機構投資者最近對公司的持倉進行了調整。Kestra Advisory Services LLC 在第四季度將其在 Cingulate 股票中的持倉增加了 29.8%。Kestra Advisory Services LLC 現在擁有 122,000 股公司股票，價值 $529,000，此前在此期間又收購了 27,979 股。Geode Capital Management LLC 在第四季度將其在 Cingulate 股票中的持倉增加了 43.9%。Geode Capital Management LLC 現在擁有 61,035 股公司股票，價值 $265,000，此前在此期間又收購了 18,629 股。DRW Securities LLC 在第四季度購買了 Cingulate 的新頭寸，價值約為 $255,000。XTX Topco Ltd 在第四季度購買了 Cingulate 的新頭寸，價值約為 $90,000。最後，Quadrature Capital Ltd 在第四季度購買了 Cingulate 的新股份，價值約為 $66,000。對沖基金和其他機構投資者持有公司股票的 41.31%。</p>
</div><h2>Cingulate Company Profile</h2>
<div class="lb-trans"><h2>Cingulate 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.</p>
<div class="lb-trans"><p>Cingulate Inc 是一家生物製藥公司，專注於開發用於治療美國注意力缺陷/多動障礙和焦慮的藥物。該公司的興奮劑藥物包括 CTx-1301（右甲基苯丙胺），目前處於三期臨牀試驗階段，以及 CTx-1302（右旋安非他命），目前正在進行新藥申請開發，旨在治療兒童、青少年和成人的注意力缺陷/多動障礙。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Cingulate</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Cingulate</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0lORw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=CING"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Cingulate Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 $1,000 在 Cingulate 嗎？</h2>
</div><p>Before you consider Cingulate, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Cingulate 之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cingulate wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每天推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買... 而 Cingulate 並不在名單上。</p>
</div><p>While Cingulate currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Cingulate 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Cingulate (CING) 將在週四公佈季度財報